Keywords
Proton Pump Inhibitor
Restriction Form
How to Cite
Abstract
Based on data on the use of PPI class drugs for the last 6 months, at December 2020-May 2021 at RSUDZA, the PPI drug class is among the drugs that are widely used every year, it is also prescribed for use other than cases of gastric acid secretion disorders and hematemesis melena, it can have an impact on optimization of drug spending costs so that if the hospital cannot control the drug spending budget and it can have an impact on the hospital's cash flow. This study aims to analyze the cost minimization of PPI (proton pump inhibitor) therapy in surgical inpatients at RSUD dr. Zainoel Abidin uses a restriction form. This study is an analytical intervention study with a prospective method and based on inclusion criteria by looking at the medical records of inpatients Neurosurgery and Orthopedics in Raudhah 3,4, and 5 by filling out the research tool used is the request sheet for restriction drugs of the PPI (Proton Pump Inhibitor) class., data collection was carried out from July-October 2021 using purposive sampling. The cost analysis used in this study is CMA (Cost Minimization Analysis), Chi-Square test to see the effect between two groups of variables, Kolmogorov Smirnove normality test to analyze data normality, and Mann Whitney to see the mean difference between groups pretest-posttest.
The results showed that the use of PPI therapy in this study mostly used Omeprazole 40 mg iv therapy is 98%. There was an effect of giving a PPI restriction form to decrease the frequency of using Omeprazole 40 mg iv to every 24 hours for prophylactic statistically (p<0.000). Analysis of the cost of CMA in neurosurgery patients found that there was no decrease in the cost of Omeprazole 40 mg iv therapy in the restriction form treatment group, analysis of the cost of CMA in orthopedic surgery patients found a decrease in the cost of Omeprazole 40 mg iv therapy in the treatment group using the restriction form. Factors that influence the cost analysis in this study are length of stay, types of other drug items obtained during treatment, type of surgery, and duration of use of PPI class therapy.
References
Baltussen R , Niessen L. Priority setting of health interventions: the need for multi-criteria decision analysis. Cost Effectiveness and Resource Allocation 2006 ; 4 : 14.
Buckley,MS, Park AS,Anderson CS, Impact of a Clinical Pharmacist Stress Ulcer Prophylaxis Management program on Inappropriate Use In Hospitalized patients. Am J of Med 2015;128:05-319.
Caro JJ, Salas M, Ward A. Healing and relapse rates ingastroesophageal reflux disease treated with the newer pro-ton-pump inhibitors lansoprazole, rabeprazole, and pantop-razole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials. Clin Ther 2001;23(7): 998–1017.
Chandra, Adi. ―Analisis Minimalisasi Biaya Anestesi Umum Propofol Target Controlled Infusion (TCI) Dan Anestesi Inhalasi Di RSUP Sanglah‖. Tesis. Program Pascasarjana Universitas Udayana (2015): h. 1, 26, 27.
Cunningham FG, Levono KJ, Bloom SL, Spong CY, Dashe JS, Hofman BL, et al, Drugs Affecting Gastrointestinal Function. In: Brunton L, editor. Godman & Gilman’s the Pharmacological Basis of Therapeutics. 12 th ed. Mc Graw Hill: 2014 p. 1037.
Gisbert JP, Gonzalez L, Calvet X, Roque M, Gabriel R, PajaresJM. Proton pump inhibitors versus H2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer.Aliment Pharmacol Ther 2001; 15(7): 917–26.
Granet-Schoeller M, Ducamp M, Gastrointestinal Disorder. In: Dipiro J, Schwinghammer T, editors. Pharmacotherapy Handbook. 9th ed. Mc Graw Hill: 2015. P.251.
Guillamondegui OD, Gunter OLJ, Bonadies J a, Coates JE, Kurek SJ, De Moya M a, et al. Practice management guidelines for stress ulcer prophylaxis. East Assoc Surg Trauma [Internet]. 2008;1–24. Available from: http://www.east.org/resources/treatment-guidelines/
Helen Dakin, Sarah Wordsworth. Cost-Minimization analysis versus cost-effectiveness analysis, revisited. Health economics Research Centre, University of Oxford, UK. 22: 22-34,2013.
Hoogerwerf, W. A. dan P.J. Pasricha. 2008. Pharmacotherapy of Gastric Acidity. Peptic Ulcers and Gastroesophageal Reflux Disease. Dalam Manual of Pharmacology and Theraupetics. Editor Brunton, L., K. Parker, D Blumenthal dan I .Buxton. Chpter 37th.The Mc Graw-Hill Companies.Inc: USA
Kahrilas PJ, Shaheen NJ, Vaezi MF, Hiltz SW, Black E, Modlin IM, dkk. (Oktober 2008). "Pernyataan Posisi Medis Asosiasi Gastroenterologi Amerika tentang pengelolaan penyakit refluks gastroesofageal". Gastroenterologi. 135 (4): 1383–1391, 1391.e1-5. doi :10.1053/j.gastro.2008.08.045 . PMID 18789939 .
Kementrian Kesehatan Republik Indonesia. Pedoman Penerapan Kajian Farmakoekonomi. Jakarta: 2013
Lacy, C. F., Armstrong, L., Golgman, M. P., Lance, L. L., 2008, Drug Information Handbook, 17th ed., Lexi-Copm Inc., New York.
Murti, Tri Andayani, Farmakoekonomi Prinsip dan Metodologi. Yogyakarta: Bursa Ilmu, 2013.
Ganet-Schoeller M, Ducamp M. Gastrointestinal Disorder. In: Dipiro J, Schwinghammer T, editors. Pharmacotherapy Handbook. 9th ed. Mc Graw Hill; 2015. p. 251.
Raifuddin, 2012. Hubungan Pola Mahasiswan dengan Penyakit Gastritis pada Mahasiswa Kedokteran Angkatan 2010 di FKIK UN. Syarif Hidayatullah. Skripsi: Program Studi Ilmu Kedokteran UIN Syarif Hidayatullah Jakarta.
Tjandrawinata, Raymond R. Peran Farmakoekonomi dalam Penentuan Kebijakan yang Berkaitan dengan Obat-obatan. Jakarta: Dexa Group, 2016.
Helen Dakin, Sarah Wordsworth. Cost-Minimization analysis versus cost-effectiveness analysis, revisited. Health economics Research Centre, University of Oxford, UK. 22: 22-34,2013.
Ketentuan Lisensi
Artikel yang diterbitkan oleh Journal of Medical Science (JMS) menggunakan lisensi Creative Commons Attribution 4.0 International (CC BY 4.0), kecuali dinyatakan lain pada artikel atau materi tertentu. Hak cipta tetap dimiliki oleh penulis.
Lisensi ini memperbolehkan siapa pun untuk:
- Berbagi: menyalin dan menyebarluaskan materi dalam media atau format apa pun.
- Mengadaptasi: mengolah, mengubah, menerjemahkan, dan mengembangkan materi untuk tujuan apa pun, termasuk komersial.
Penggunaan tersebut harus memenuhi ketentuan berikut:
- Memberikan atribusi yang layak kepada penulis dan menyebutkan sumber publikasi di JMS.
- Menyertakan tautan ke lisensi CC BY 4.0 dan DOI atau tautan artikel apabila tersedia.
- Menunjukkan perubahan yang dilakukan tanpa memberi kesan bahwa penulis atau JMS mendukung penggunaan tersebut.
- Tidak menerapkan ketentuan hukum atau pembatasan teknologi yang menghalangi pihak lain menggunakan materi sebagaimana diizinkan lisensi.
Materi pihak ketiga yang tidak tercakup dalam lisensi artikel mengikuti ketentuan yang dicantumkan pada materi tersebut. Lisensi tidak menghapus kewajiban menghormati hak privasi, hak moral, atau hak lain yang relevan.
Lisensi artikel yang telah diterbitkan sebelumnya tetap mengikuti keterangan pada masing-masing artikel. Ketentuan lengkap tersedia pada teks hukum lisensi CC BY 4.0.